ESR1 and breast carcinoma: It has been reported that ER-negative and high-grade breast cancers were consistently associated with a better response to chemotherapy (Rouzier et al., 2005b; Kurozumi et al., 2015); and different molecular subtypes of breast cancers based on PAM50 classifier responded differently to neoadjuvant chemotherapy (Parker et al., 2009).